Cargando…

Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities

AIMS/INTRODUCTION: Although several noninvasive predictive markers for fatty liver and metabolic markers have been used for fatty liver prediction, whether such markers can also predict metabolic‐associated fatty liver disease (MAFLD) remains unclear. We aimed to examine the ability of existing fatt...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Akira, Yamada, Gen, Kimura, Takeshi, Hagiwara, Yasuhiro, Yamaguchi, Satoko, Kurakawa, Kayo Ikeda, Nangaku, Masaomi, Yamauchi, Toshimasa, Matsuyama, Yutaka, Kadowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951571/
https://www.ncbi.nlm.nih.gov/pubmed/36566480
http://dx.doi.org/10.1111/jdi.13966
_version_ 1784893414635995136
author Okada, Akira
Yamada, Gen
Kimura, Takeshi
Hagiwara, Yasuhiro
Yamaguchi, Satoko
Kurakawa, Kayo Ikeda
Nangaku, Masaomi
Yamauchi, Toshimasa
Matsuyama, Yutaka
Kadowaki, Takashi
author_facet Okada, Akira
Yamada, Gen
Kimura, Takeshi
Hagiwara, Yasuhiro
Yamaguchi, Satoko
Kurakawa, Kayo Ikeda
Nangaku, Masaomi
Yamauchi, Toshimasa
Matsuyama, Yutaka
Kadowaki, Takashi
author_sort Okada, Akira
collection PubMed
description AIMS/INTRODUCTION: Although several noninvasive predictive markers for fatty liver and metabolic markers have been used for fatty liver prediction, whether such markers can also predict metabolic‐associated fatty liver disease (MAFLD) remains unclear. We aimed to examine the ability of existing fatty liver or metabolic markers to predict MAFLD. MATERIALS AND METHODS: Participants in a high‐volume center in Tokyo were classified into groups with and without MAFLD, based on the presence of metabolic abnormalities and fatty liver diagnosed through abdominal ultrasonography, between 2008 and 2018. The diagnostic abilities of three fatty liver markers: fatty liver index (FLI), hepatic steatosis index (HSI), and lipid accumulation product (LAP), and three common metabolic markers: waist‐to‐height ratio (WHR), body mass index (BMI), and waist circumference (WC), for predicting MAFLD, were evaluated. Analyses stratified by MAFLD subtypes were performed. RESULTS: Of 92,374 individuals, 19,392 (36.1%) had MAFLD. The diagnostic performances for MAFLD prediction, measured as c‐statistics, for FLI, HSI, LAP, WHR, BMI, and WC were 0.906, 0.892, 0.878, 0.844, 0.877, and 0.878, respectively. Optimal cutoff values for diagnosing MAFLD for FLI, HSI, LAP, WHR, BMI, and WC were 20.3, 32.7, 20.0, 0.49, 22.9, and 82.1, respectively. Analyses stratified by MAFLD subtypes, based on BMI and metabolic/glycemic abnormalities, suggested that FLI and HSI had acceptable (c‐statistics >0.700) diagnostic abilities throughout all the analyses. CONCLUSIONS: All six markers were excellent predictors of MAFLD in diagnosing among the general population, with FLI and HSI particularly useful among all sub‐populations.
format Online
Article
Text
id pubmed-9951571
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99515712023-02-25 Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities Okada, Akira Yamada, Gen Kimura, Takeshi Hagiwara, Yasuhiro Yamaguchi, Satoko Kurakawa, Kayo Ikeda Nangaku, Masaomi Yamauchi, Toshimasa Matsuyama, Yutaka Kadowaki, Takashi J Diabetes Investig Articles AIMS/INTRODUCTION: Although several noninvasive predictive markers for fatty liver and metabolic markers have been used for fatty liver prediction, whether such markers can also predict metabolic‐associated fatty liver disease (MAFLD) remains unclear. We aimed to examine the ability of existing fatty liver or metabolic markers to predict MAFLD. MATERIALS AND METHODS: Participants in a high‐volume center in Tokyo were classified into groups with and without MAFLD, based on the presence of metabolic abnormalities and fatty liver diagnosed through abdominal ultrasonography, between 2008 and 2018. The diagnostic abilities of three fatty liver markers: fatty liver index (FLI), hepatic steatosis index (HSI), and lipid accumulation product (LAP), and three common metabolic markers: waist‐to‐height ratio (WHR), body mass index (BMI), and waist circumference (WC), for predicting MAFLD, were evaluated. Analyses stratified by MAFLD subtypes were performed. RESULTS: Of 92,374 individuals, 19,392 (36.1%) had MAFLD. The diagnostic performances for MAFLD prediction, measured as c‐statistics, for FLI, HSI, LAP, WHR, BMI, and WC were 0.906, 0.892, 0.878, 0.844, 0.877, and 0.878, respectively. Optimal cutoff values for diagnosing MAFLD for FLI, HSI, LAP, WHR, BMI, and WC were 20.3, 32.7, 20.0, 0.49, 22.9, and 82.1, respectively. Analyses stratified by MAFLD subtypes, based on BMI and metabolic/glycemic abnormalities, suggested that FLI and HSI had acceptable (c‐statistics >0.700) diagnostic abilities throughout all the analyses. CONCLUSIONS: All six markers were excellent predictors of MAFLD in diagnosing among the general population, with FLI and HSI particularly useful among all sub‐populations. John Wiley and Sons Inc. 2022-12-25 /pmc/articles/PMC9951571/ /pubmed/36566480 http://dx.doi.org/10.1111/jdi.13966 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Okada, Akira
Yamada, Gen
Kimura, Takeshi
Hagiwara, Yasuhiro
Yamaguchi, Satoko
Kurakawa, Kayo Ikeda
Nangaku, Masaomi
Yamauchi, Toshimasa
Matsuyama, Yutaka
Kadowaki, Takashi
Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
title Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
title_full Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
title_fullStr Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
title_full_unstemmed Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
title_short Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
title_sort diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951571/
https://www.ncbi.nlm.nih.gov/pubmed/36566480
http://dx.doi.org/10.1111/jdi.13966
work_keys_str_mv AT okadaakira diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT yamadagen diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT kimuratakeshi diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT hagiwarayasuhiro diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT yamaguchisatoko diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT kurakawakayoikeda diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT nangakumasaomi diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT yamauchitoshimasa diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT matsuyamayutaka diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities
AT kadowakitakashi diagnosticabilityusingfattyliverandmetabolicmarkersformetabolicassociatedfattyliverdiseasestratifiedbymetabolicglycemicabnormalities